Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
January 29 2021 - 4:30PM
AMF REGULATED
INFORMATIONMontrouge, France, January 29, 2021
Half-Year Report on the DBV Technologies
Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today issued the Half-Year report on its
liquidity contract with ODDO BHF.
As of December 31, 2020, the following assets
appeared on the liquidity account:
- 112,302 DBV Technologies shares;
- € 229,086.53.
Upon signing the liquidity contract in July
2018, the following resources appeared on the liquidity
account:
- 24,313 DBV Technologies ordinary shares;
- € 682,454.94.
Number of transactions executed during the
second half-year of 2020:
- Purchase: 1,180
- Sale: 1,136
Over the same period, the volumes traded
represented:
- 517,291 DBV Technologies ordinary shares purchased for
€2,005,858.40
- 458,090 DBV Technologies ordinary shares sold for
€1,841,496.60
About DBV Technologies DBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France and offices in Bagneux, France, and North American
operations in Summit, NJ and New York, NY. The Company’s ordinary
shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), and the Company’s ADSs (each representing
one-half of one ordinary share) are traded on the Nasdaq Global
Select Market (Ticker: DBVT).
DBV Investor Relations Contact
Anne PollakDBV Technologies+1
857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Apr 2023 to Apr 2024